- Home
- KF vs INO Comparison
KF vs INO Comparison
Compare KF & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- INO
- Stock Information
- Founded
- KF 1984
- INO 1979
- Country
- KF United States
- INO United States
- Employees
- KF N/A
- INO N/A
- Industry
- KF Investment Managers
- INO Medical/Dental Instruments
- Sector
- KF Finance
- INO Health Care
- Exchange
- KF Nasdaq
- INO Nasdaq
- Market Cap
- KF 128.4M
- INO 136.6M
- IPO Year
- KF N/A
- INO 1998
- Fundamental
- Price
- KF $36.21
- INO $2.42
- Analyst Decision
- KF
- INO Buy
- Analyst Count
- KF 0
- INO 5
- Target Price
- KF N/A
- INO $8.80
- AVG Volume (30 Days)
- KF 18.4K
- INO 1.1M
- Earning Date
- KF 01-01-0001
- INO 11-10-2025
- Dividend Yield
- KF N/A
- INO N/A
- EPS Growth
- KF N/A
- INO N/A
- EPS
- KF N/A
- INO N/A
- Revenue
- KF N/A
- INO $182,337.00
- Revenue This Year
- KF N/A
- INO N/A
- Revenue Next Year
- KF N/A
- INO $14,751.49
- P/E Ratio
- KF N/A
- INO N/A
- Revenue Growth
- KF N/A
- INO N/A
- 52 Week Low
- KF $18.30
- INO $1.30
- 52 Week High
- KF $25.56
- INO $5.80
- Technical
- Relative Strength Index (RSI)
- KF 77.02
- INO 49.71
- Support Level
- KF $35.67
- INO $2.36
- Resistance Level
- KF $36.50
- INO $2.67
- Average True Range (ATR)
- KF 0.59
- INO 0.13
- MACD
- KF 0.25
- INO -0.01
- Stochastic Oscillator
- KF 100.00
- INO 37.72
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.